Formoterol Fumarate

"Formoterol Fumarate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An ADRENERGIC BETA-2 RECEPTOR AGONIST with a prolonged duration of action. It is used to manage ASTHMA and in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Descriptor ID	D000068759
MeSH Number(s)	D02.033.100.291.425 D02.092.063.291.425
Concept/Terms	Formoterol Fumarate Formoterol Fumarate Formoterol Fumarate, ((R,R)-(+-))-isomer 3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate BD 40A BD 40A Formoterol Formoterol Eformoterol Oxis Oxis Arformoterol Arformoterol Formoterol, ((R,R)-(+-))-isomer Foradil Foradil

Below are MeSH descriptors whose meaning is more general than "Formoterol Fumarate".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Alcohols [D02.033]
Amino Alcohols [D02.033.100]
Ethanolamines [D02.033.100.291]
Formoterol Fumarate [D02.033.100.291.425]
Amines [D02.092]
Amino Alcohols [D02.092.063]
Ethanolamines [D02.092.063.291]
Formoterol Fumarate [D02.092.063.291.425]

Below are MeSH descriptors whose meaning is related to "Formoterol Fumarate".

Below are MeSH descriptors whose meaning is more specific than "Formoterol Fumarate".

Formoterol Fumarate
Budesonide, Formoterol Fumarate Drug Combination
Mometasone Furoate, Formoterol Fumarate Drug Combination

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Formoterol Fumarate" by people in this website by year, and whether "Formoterol Fumarate" was a major or minor topic of these publications.

Bar chart showing 15 publications over 13 distinct years, with a maximum of 2 publications in 2016 and 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2006	0	1	1
2007	0	1	1
2009	0	1	1
2010	0	1	1
2011	0	1	1
2012	0	1	1
2013	0	1	1
2014	0	1	1
2016	1	1	2
2019	0	1	1
2023	0	2	2
2024	0	1	1

Below are the most recent publications written about "Formoterol Fumarate" by people in Profiles.

Panettieri RA, Chipps BE, Skolnik N, George M, Murphy K, Lugogo N. The Use of Albuterol/Budesonide as Reliever Therapy to Reduce Asthma Exacerbations. J Allergy Clin Immunol Pract. 2024 04; 12(4):882-888.

View in: PubMed
Mosnaim GS, Hoyte FCL, Safioti G, Brown R, Hill TD, Li T, Sagalovich K, DePietro M, Wechsler ME. Effectiveness of a Maintenance and Reliever Digihaler System in Asthma: 24-Week Randomized Study (CONNECT2). J Allergy Clin Immunol Pract. 2024 02; 12(2):385-395.e4.

View in: PubMed
Mintz M, Barjaktarevic I, Mahler DA, Make B, Skolnik N, Yawn B, Zeyzus-Johns B, Hanania NA. Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review. Mayo Clin Proc. 2023 02; 98(2):301-315.

View in: PubMed
Koziol-White C, Johnstone TB, Corpuz ML, Cao G, Orfanos S, Parikh V, Deeney B, Tliba O, Ostrom RS, Dainty I, Panettieri RA. Budesonide enhances agonist-induced bronchodilation in human small airways by increasing cAMP production in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2020 02 01; 318(2):L345-L355.

View in: PubMed
Forkuo GS, Kim H, Thanawala VJ, Al-Sawalha N, Valdez D, Joshi R, Parra S, Pera T, Gonnella PA, Knoll BJ, Walker JK, Penn RB, Bond RA. Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by ?2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice. Am J Respir Cell Mol Biol. 2016 08; 55(2):234-42.

View in: PubMed
Tashkin DP, Moore GE, Trudo F, DePietro M, Chipps BE. Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma. J Allergy Clin Immunol Pract. 2016 Jul-Aug; 4(4):705-12.

View in: PubMed
Tashkin DP, Chipps BE, Trudo F, Zangrilli JG. Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses. J Asthma. 2014 Aug; 51(6):603-9.

View in: PubMed
Moodley T, Wilson SM, Joshi T, Rider CF, Sharma P, Yan D, Newton R, Giembycz MA. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease. Mol Pharmacol. 2013 Apr; 83(4):894-906.

View in: PubMed
Murphy KR, Uryniak T, Martin UJ, Zangrilli J. The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma. Drugs R D. 2012 Mar 01; 12(1):9-14.

View in: PubMed
Zangrilli J, Mansfield LE, Uryniak T, O'Brien CD. Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial. Ann Allergy Asthma Immunol. 2011 Sep; 107(3):258-65.e2.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement